Beijing Luzhu Biotechnology Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2023. It is expected that the Group will experience a significant decrease in net loss and a decrease in adjusted net loss for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The group expects to record a net loss of not more than RMB 80 million for the six months ended June 30, 2023, representing a decrease of not less than 87% as compared to the net loss of approximately RMB 652 million for the six months ended June 30, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24.5 HKD | 0.00% | -3.54% | -18.06% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.06% | 636M | |
-1.93% | 89.49B | |
+2.24% | 40.67B | |
-12.97% | 33.15B | |
+61.72% | 26.45B | |
-20.71% | 14.69B | |
-7.31% | 12.89B | |
-12.64% | 11.54B | |
-42.60% | 11.34B | |
+4.27% | 8.84B |
- Stock Market
- Equities
- 2480 Stock
- News Beijing Luzhu Biotechnology Co., Ltd.
- Beijing Luzhu Biotechnology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023